Efficacy of Mizoribine (MZR) treatment for gastrointestinal symptoms in kidney transplant recipients using mycophenolate mofetil (MMF). - Open-label, multicenter, randomized, controlled trial &#8211;

Efficacy of Mizoribine (MZR) treatment for gastrointestinal symptoms in kidney transplant recipients using mycophenolate mofetil (MMF). - Open-label, multicenter, randomized, controlled trial &#8211; - Mizoribine Convert Study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008649

Enrollment

200

Registered

2012-08-08

Start date

2012-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney transplantation

Interventions

mizoribine mycophenolate mofetil

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Conduct a GSRS survey during MMF treatment, and patients included if GSRS score 3 (on a scale of 1 to 7) applies to more than 2 items, or GSRS score 4 applies to at least one of the following: (1):Abdominal pain, (2):Heartburn, (10):Decreased passage of stools, (11):Increased passage of stools, (12):Loose stools, (14):Urgent need for defecation. Patients who had a detailed briefing of the trial with explanatory documents prior to the enrollment, and voluntarily signed a consent form.

Exclusion criteria

Exclusion criteria: 1. currently undergoing acute rejection 2. positive for DSA 3. serum creatinine level of less than 3mg/dL 4. a severe infection other than viral infection 5. white blood cell counts of less than 3,000/mm3 6. pregnant women and women suspected of being pregnant 7. aged 19 or younger 8. considered inappropriate by the doctor

Design outcomes

Primary

Measure	Time frame
Difference of GSRS results between the 1st day and a month later.	—

Countries

Japan

Contacts

Public ContactHideki Ishida

Tokyo Women Medical University Dep. Urology

hishida@kc.twmu.ac.jp03-3353-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026

Efficacy of Mizoribine (MZR) treatment for gastrointestinal symptoms in kidney transplant recipients using mycophenolate mofetil (MMF). - Open-label, multicenter, randomized, controlled trial &amp;#8211;